Ikarian Capital’s Cumberland Pharmaceuticals CPIX Stock Holding History

Ikarian Capital’s Portfolio CPIX Stock Details CPIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.26M	Sell	503,153 -50,000	-9%	-$240K	0.35%	71
2026 Q1	$1.8M	Sell	553,153 -2,779	-0.5%	-$10.7K	0.15%	103
2025 Q4	$2.21M	Hold	555,932	–	–	0.17%	98
2025 Q3	$1.73M	Sell	555,932 -40,000	-7%	-$133K	0.18%	106
2025 Q2	$2M	Sell	595,932 -144,068	-19%	-$682K	0.38%	68
2025 Q1	$3.13M	Buy	+740,000	New	+$3.07M	0.39%	58

Other funds holding CPIX

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ikarian Capital's CPIX Position: Q2 2026 in Review

Ikarian Capital reduced its Cumberland Pharmaceuticals (CPIX) stake by 9% in Q2 2026, selling an estimated $240K and leaving 503,153 shares worth $3.26M. The position accounts for 0.35% of the portfolio, ranked #71.

Ikarian Capital first reported a position in CPIX in Q1 2025 and has held it in 6 quarters since. 32 funds tracked by Wall St. Rank hold CPIX as of Q2 2026.

Ikarian Capital held 503,153 shares of Cumberland Pharmaceuticals worth $3.26M as of Q2 2026.
Ikarian Capital sold 50,000 Cumberland Pharmaceuticals shares in Q2 2026, an estimated $240K.
Cumberland Pharmaceuticals made up 0.35% of Ikarian Capital's portfolio in Q2 2026, its #71 holding.
Ikarian Capital first reported a position in Cumberland Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
32 funds tracked by Wall St. Rank held Cumberland Pharmaceuticals as of Q2 2026.

Based on Ikarian Capital's 13F filing for Q2 2026, filed 14 Aug 2026.